智能生物解决方案有限公司美股招股说明书（2025-09-15版）

INTELLIGENT BIO SOLUTIONS, INC. This Prospectus Supplement, dated September 15, 2025, supplements that certain Prospectus filed by Intelligent Bio Solutions, Inc.(the “Company”) with the Securities and Exchange Commission (the “SEC”) and dated March 27, 2024 (the “Prospectus”) and shouldbe read in conjunction with the Prospectus. SELLING STOCKHOLDERS The following updates the table under the section entitled “Selling Stockholders” of the Prospectus, to account for a transfer of shareslisted in such table that the Company is aware of since the date of the Prospectus. On May 6, 2025, Altium Growth Fund, LP(“Altium”) transferred to Warberg WF XII LP (“Warberg”), in a transaction exempt from the registration requirements of theSecurities Act of 1933, as amended (the “Securities Act”), Series H-1 Warrants exercisable for an aggregate of 439,560 shares of theCompany’s common stock. On July 24, 2025, Altium transferred to Warberg, in a transaction exempt from the registrationrequirements of the Securities Act, Series H-2 Warrants exercisable for an aggregate of 439,560 shares of the Company’s commonstock. As a result of these assignments to Warberg, Altium no longer holds any Series H-1 Warrants or Series H-2 Warrants. The table, therefore, is amended by adding the information in the following table for Warberg as a Selling Stockholder and removingAltium as a Selling Stockholder. The aggregate number of shares registered pursuant to the Prospectus has not increased as a result ofthis amendment. Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons andentities named in the table have sole voting and investment power with respect to their beneficially owned securities. Percentage ofbeneficial ownership is calculated based on 9,028,712 shares of common stock outstanding as of September 10, 2025. †Includes common stock issuable upon exercise of the Warrants.*Less than 1%. (1) Consists of 73,368 shares directly held by Warberg WF XII LP (“Warberg”); 189,560 shares underlying Series H-1 Warrants;439,560 shares underlying Series H-2 Warrants; and 500,000 shares underlying Series J Warrants held by Warberg. The securities aredirectly held by Warberg WF XII LP and may be deemed to be beneficially owned by Daniel Warsh, who has investment anddispositive power over the securities. The warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restrictsthe Selling Stockholder from exercising that portion of the warrants that would result in the Selling Stockholder and its affiliatesowning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of theSelling Stockholder is 716 Oak St. Winnetka, IL 60093.